These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16757970)

  • 1. Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates.
    Santini D; Caraglia M; Vincenzi B; Holen I; Scarpa S; Budillon A; Tonini G
    Nat Clin Pract Oncol; 2006 Jun; 3(6):325-38. PubMed ID: 16757970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
    Szafran AA; Folks K; Warram J; Chanda D; Wang D; Zinn KR
    Cancer Biol Ther; 2009 Jun; 8(12):1109-16. PubMed ID: 19652526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.
    Tonyali O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2010 Nov; 11(16):2715-25. PubMed ID: 20977404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
    Budman DR; Calabro A
    Oncology; 2006; 70(2):147-53. PubMed ID: 16645328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects.
    Marra M; Abbruzzese A; Addeo R; Del Prete S; Tassone P; Tonini G; Tagliaferri P; Santini D; Caraglia M
    Curr Cancer Drug Targets; 2009 Nov; 9(7):791-800. PubMed ID: 20025567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
    Altundag K; Altundag O; Morandi P; Gunduz M
    Urology; 2005 Jan; 65(1):211-2; author reply 212. PubMed ID: 15667906
    [No Abstract]   [Full Text] [Related]  

  • 7. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
    Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
    Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
    Odri GA; Dumoucel S; Picarda G; Battaglia S; Lamoureux F; Corradini N; Rousseau J; Tirode F; Laud K; Delattre O; Gouin F; Heymann D; Redini F
    Cancer Res; 2010 Oct; 70(19):7610-9. PubMed ID: 20841471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
    Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.
    Dos Santos MP; de Farias CB; Roesler R; Brunetto AL; Abujamra AL
    Oncol Rep; 2014 Feb; 31(2):955-68. PubMed ID: 24316794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.
    Magnetto S; Boissier S; Delmas PD; Clezardin P
    Int J Cancer; 1999 Oct; 83(2):263-9. PubMed ID: 10471537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
    Duivenvoorden WC; Vukmirović-Popović S; Kalina M; Seidlitz E; Singh G
    Br J Cancer; 2007 May; 96(10):1526-31. PubMed ID: 17437017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.
    Neville-Webbe HL; Coleman RE; Holen I
    Br J Cancer; 2010 Mar; 102(6):1010-7. PubMed ID: 20160726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
    Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
    Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
    J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects and anticancer applications of bisphosphonates.
    Morgan G; Lipton A
    Semin Oncol; 2010 Oct; 37 Suppl 2():S30-40. PubMed ID: 21111246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
    Mundy GR; Yoneda T; Hiraga T
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
    Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
    Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid in the management of metastatic bone disease.
    Santini D; Fratto ME; Vincenzi B; Galluzzo S; Tonini G
    Expert Opin Biol Ther; 2006 Dec; 6(12):1333-48. PubMed ID: 17223741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antitumor potential of bisphosphonates.
    Clézardin P
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):33-42. PubMed ID: 12584693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.